ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2022
Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States.
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- A Diagnostic Dilemma in a Breast Cancer Patient on Tamoxifen: Perihepatic Endometriosis Masquerading as Metastatic Disease.International medical case reports journal · 2026Article
- Two Cases of Hepatic Epithelioid Hemangioendothelioma Misdiagnosed With Hepatic Veno-Occlusive Disease.Case reports in hepatology · 2026Article
- Hepatic epithelioid hemangioendothelioma managed with minimally invasive surgery: A case report.World journal of clinical cases · 2025Article
- Review
- Hepatic Endometriosis Misdiagnosed as Hepatic Epithelioid Hemangioendothelioma.Case reports in hepatology · 2025Article
- Nab-Paclitaxel Based Chemotherapy in the Treatment of Advanced Epithelioid Hemangioendothelioma: A Single-Institution Experience.Cancer management and research · 2025Article
- CAMTA1-immunonegative epithelioid hemangioendotheliomas of the liver: a clinicopathological and molecular analysis of seven cases.Frontiers in oncology · 2025Article
- Diaphragm epithelioid hemangioendothelioma: a rare case report.BMC geriatrics · 2024Article
- Long-term prognosis and treatment modalities of hepatic epithelioid hemangioendothelioma: a retrospective study of 228 patients.BMC cancer · 2024Article
- Image-guided percutaneous ablation of hepatic epithelioid hemangioendothelioma.Abdominal radiology (New York) · 2024Article
- CT appearances and classification of hepatic epithelioid hemangioendothelioma.Insights into imaging · 2023Article
- Hepatic epithelioid hemangioendothelioma: pitfalls in the treatment of a rare liver malignancy.Translational gastroenterology and hepatology · 2023Article
- Epithelioid Hemangioendothelioma: Incidence, Mortality, Prognostic Factors, and Survival Analysis Using the Surveillance, Epidemiology, and End Results Database.Journal of oncology · 2022Article
- Clinical, Histopathological, and Immunophenotypic Spectrum of Hepatic Epithelioid Hemangioendothelioma: Eight Years' Data of a Tertiary Care Center from North India.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundWe analyzed the outcomes of patients with hepatic epithelioid hemangioendothelioma (HEHE) in the United States after stratification by their most definitive treatment.
methodsThe National Cancer Data Base was used to identify patients with HEHE between 2004 and 2018. Patients were divided in four treatment groups: no surgical therapy, ablation, liver resection or liver transplantation. Demographics and clinical characteristics were compared, and Kaplan Meier functions and Cox-regression were used for unadjusted and adjusted survival analyses.
resultsAmong a total of 334 patients, 218 (65.2%) were managed non-surgically, 74 (22.1%) underwent hepatic resections, 35 (10.4%) underwent liver transplantation and 7 (2.1%) underwent ablations. The overall median survival was 111 months (95%CI 73-149) after liver transplantation, 69 months (95%CI 45-92) after hepatic resection, 38 months (95%CI 0-78) after ablation and 80 months (95%CI 70-90) for patients managed by watchful waiting (P < 0.001). After adjustment, patients who underwent liver transplantation were found to have a better survival when compared to other therapies (Hazard Ratio: 0.61, 95% Confidence Interval: 0.38-0.97, p = 0.035).
conclusionsThis study reports the outcomes of the largest cohort of patients with HEHE. The longest survival was observed after liver transplantation, followed by non-surgical management and hepatic resection. Because of selection bias, future studies to better characterize what criteria should be used for the selection of treatment modalities for HEHE are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.